AlzChem AG sets price range for its IPO from EUR 20.00 to 27.00 per share
• AlzChem is a vertically integrated specialty chemicals producer based on the NCN chain with leading positions in selected niche markets.
• Offer period to start on January 27, 2017, and is expected to end on February 8, 2017.
• Total transaction volume of EUR 162.6 to 219.5 million expected (assuming full exercise of greenshoe option).
• The company expects to raise gross proceeds of EUR 40.0 to 54.0 million from a capital increase against cash contributions.
• Should the placement of existing and new shares take place as planned, the company expects a free float of 56.8% (62.5% assuming the greenshoe option is fully exercised).
Trostberg, January 26, 2017 – AlzChem AG (together with its subsidiaries hereinafter “AlzChem”), a vertically integrated specialty chemicals producer with a leading market position in selected niche markets, set today the terms of the offer for its planned IPO in the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange. The securities prospectus was approved today by the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin). The offer consists of a public offer in the Federal Republic of Germany and the Grand Duchy of Luxembourg as well as private placements in certain jurisdictions outside these countries and the United States of America in reliance on Regulation S under the U.S. Securities Act of 1933, as amended. In the United States of America, the shares will be offered and sold exclusively to qualified institutional buyers as defined by Rule 144A of the U.S. Securities Act of 1933, as amended.
Offer period to begin on January 27, 2017
The bookbuilding process will begin on Friday, January 27, 2017, and is expected to end on Wednesday, February 8, 2017. The price range has been set at EUR 20.00 to 27.00 per share. The offer comprises an aggregate of 8,129,000 ordinary bearer shares with no par value. The offer includes 2,000,000 newly issued ordinary bearer shares with no par value from a capital increase against cash contributions, which will be resolved by an extraordinary general meeting of AlzChem AG on January 26, 2017, excluding the subscription rights of the existing shareholders. AlzChem AG expects to generate gross proceeds of EUR 40.0 to 54.0 million from the capital increase (at the low end and high end of the price range, respectively). In addition, the offer consists of 5,390,000 existing ordinary bearer shares with no par value from the holdings of the selling shareholders. Also, up to a maximum of 739,000 existing shares from the holdings of the selling shareholders may be placed at the offer price as part of an over-allotment and greenshoe option. Upon completion of the IPO, the free float portion of the share capital will be 56.8% (without exercising the greenshoe option) and 62.5% (assuming that the greenshoe option is fully exercised).
The placement price and the final number of shares to be placed are expected to be published on February 8, 2017. The listing of the shares of AlzChem AG is expected to take place on February 10, 2017. Delivery of the shares is expected for February 13, 2017.
Société Générale Corporate & Investment Banking and Baader Bank will manage the IPO as Joint Global Coordinators and Joint Bookrunners. Co-Lead Manager is ODDO SEYDLER BANK AG.
Proceeds to be used to finance growth
AlzChem AG plans to invest an amount of at least EUR 35 million of the net proceeds from the sale of the new shares for the construction of an additional production facility for the feed additive CreAMINO at its Trostberg site. CreAMINO is used to raise broiler chickens, for instance, and leads to improved feed utilization. The remaining net proceeds are to be used to expand existing production facilities for the food supplement Creapure, which is currently used in the sports and fitness industry. In addition, AlzChem plans to attract new target groups for Creapure.
On the basis of preliminary and unaudited IFRS figures, AlzChem generated sales of EUR 327.2 million in fiscal year 2016 (previous year: EUR 322.6 million). The increase in sales was driven by an increased demand for the products CreAMINO, Dormex and BioSELECT, in particular. In the same period, the company’s EBITDA increased from EUR 33.2 million to EUR 38.6 million (preliminary and unaudited). Prior to non-operating one-off effects in connection with the planned IPO in the amount of EUR 6.3 million the adjusted EBITDA was EUR 44.9 million. Hence, due to growth dynamics in the business segment Specialty Chemicals, the EBITDA margin on group level increased significantly from 10.3% in the previous year to 11.8% in 2016. The adjusted EBITDA margin for 2016 amounted to 13.7%.
Ulli Seibel, CEO of AlzChem AG, explains: “We continued our growth path in fiscal year 2016 and managed to increase our profitability. With the planned investments in production capacities for the two Specialty Chemical products CreAMINO and Creapure, we want to achieve our strategic objective of growing profitably in the future. We will strive to benefit in particular from external growth drivers such as the growing world population, the trend towards healthy aging and the growing importance of energy efficiency with our products. In addition, we plan to maintain our focus on innovations in the business segment Specialty Chemicals in the future.”
Further information on the IPO is available in AlzChem AG’s securities prospectus, which was approved today by the Federal Financial Supervisory Authority.
AlzChem AG’s approved securities prospectus is available for download on the company's website
www.alzchem.com in the Investor Relations section.
About AlzChem AG
AlzChem AG, located in Trostberg, Bavaria, is a vertically integrated manufacturer of various chemical products based on the NCN chain. These are products with typical nitrogen-carbon-nitrogen bonding, which are used in a variety of industries. The company has a leading market position in selected niche markets, including the markets for feed additives and food supplements. The strategic focus of growth and the focus of the extensive research and development lie on the business segment Specialty Chemicals. The joint production and the brand portfolio protect AlzChem from potential market entries. The company has 1,480 employees at four sites in Germany and three others abroad.
Investor Relations Contact
Henryk Deter / Maximilian Breuer
Phone: +49 (0)611 - 205855-22
Fax: +49 (0)611 - 205855-66
This publication may not be published, distributed or transmitted, directly or indirectly, in or into the United States, Canada, Japan or Australia. This publication constitutes neither an offer to sell nor an invitation to buy or subscribe securities in the United States or Germany or any other jurisdiction. The shares in AlzChem AG (the “Shares”) may not be offered or sold in the United States or to or for the account or benefit of “U.S. persons” (as such term is defined in Regulation S under the Securities Act of 1933, as amended (the “Securities Act”)) absent registration or an exemption from registration under the Securities Act. The Shares have not been and will not be registered under the Securities Act. No offer or sale of securities is being made to the public outside Germany or Luxembourg. The offers in Germany and Luxembourg will be made exclusively by means of and on the basis of a prospectus published and available free of charge at www.alzchem.com.
This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The securities are only available to, and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.